{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:58:55Z","timestamp":1781873935257,"version":"3.54.5"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Introduction and importance:<\/jats:title>\n            <jats:p>Patients with rheumatoid arthritis who are treated with adalimumab have an increased risk of developing latent infections. The lethal risk of TB encephalitis as a potential manifestation after treatment with adalimumab should not be overlooked despite its rarity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>We report a case of a 19-year-old Middle Eastern female who developed cerebral tuberculosis after receiving adalimumab therapy for rheumatoid arthritis. The patient was systemically well. Her medical history included pneumonia, PCOs (polycystic ovary syndrome), and <jats:italic toggle=\"yes\">H. pylori gastritis<\/jats:italic>. Subsequently, she showed signs of anxiety after treatment with adalimumab. Magnetic resonance imaging (MRI) of the brain revealed a ring-enhancing lesion. An analysis of cerebrospinal fluid (CSF) failed to detect tuberculosis. The patient was treated and responded favorably to the tuberculosis standard four-drug anti-TB regimen (rifampicin, isoniazid, ethambutol, and pyrazinamide) and continued to show clinical improvement under ongoing treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical disscusion:<\/jats:title>\n            <jats:p>Rheumatoid arthritis patients who are treated with DMARDs are at risk of developing opportunistic infections. While most opportunistic infections are well understood and have clear symptoms, the rare occurrence of encephalitis should not be dismissed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Although rare, TB encephalitis should be considered in patients developing neurological symptoms after treatment with Adalimumab.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003450","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T14:00:13Z","timestamp":1748527213000},"page":"4661-4665","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Reactivation of cereberal tuberculosis post-adalimumab therapy for rheumatoid arthritis: a case report"],"prefix":"10.1097","volume":"87","author":[{"given":"Adnan","family":"Alghazzawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-6803","authenticated-orcid":false,"given":"Zyad","family":"Al-Frejat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Barkil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Shammas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas Abood","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"R1-20250922","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20250922","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","article-title":"Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology Criteria: a systematic review","volume":"36","author":"Alamanos","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"R3-20250922","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid arthritis: a brief overview of the treatment","volume":"27","author":"Bullock","year":"2018","journal-title":"Med Princ Pract"},{"key":"R4-20250922","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"State of the art paper tumor necrosis factor inhibitors \u2013 state of knowledge","volume":"6","author":"Lis","year":"2014","journal-title":"Arch Med Sci"},{"key":"R5-20250922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2690402","article-title":"Effect of tumor necrosis factor inhibitor therapy on osteoclasts precursors in rheumatoid arthritis","volume":"2017","author":"Perp\u00e9tuo","year":"2017","journal-title":"Biomed Res Int"},{"key":"R6-20250922","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14740338.2020.1734560","article-title":"Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa","volume":"19","author":"Tzanetakou","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R7-20250922","doi-asserted-by":"crossref","first-page":"e0186499","DOI":"10.1371\/journal.pone.0186499","article-title":"Determinants of site of tuberculosis disease: an analysis of European surveillance data from 2003 to 2014","volume":"12","author":"Sotgiu","year":"2017","journal-title":"PLoS One"},{"key":"R9-20250922","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","article-title":"Adalimumab: a review of side effects","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"R10-20250922","first-page":"e52267","article-title":"Cerebral tuberculosis after therapy with adalimumab for hidradenitis suppurativa: a rare case","volume":"16","author":"Martins","year":"2024","journal-title":"Cureus"},{"key":"R11-20250922","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.crohns.2012.02.018","article-title":"Life-threatening disseminated tuberculosis as a complication of treatment by infliximab for Crohn\u2019s disease: report of two cases, including cerebral tuberculomas and miliary tuberculosis","volume":"6","author":"Tissot","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R12-20250922","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1148\/rg.2019190109","article-title":"Extrapulmonary tuberculosis: pathophysiology and imaging findings","volume":"39","author":"Rodriguez-Takeuchi","year":"2019","journal-title":"RadioGraphics"},{"key":"R13-20250922","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.carj.2016.10.007","article-title":"Central nervous system tuberculosis: an imaging perspective","volume":"68","author":"Chaudhary","year":"2017","journal-title":"Can Assoc Radiol J"},{"key":"R14-20250922","doi-asserted-by":"crossref","first-page":"e938353","DOI":"10.12659\/AJCR.938353","article-title":"Neurotuberculosis in a patient with ulcerative colitis using long-term adalimumab: a rare case","volume":"24","author":"Bortolozzo Graciolli Facanali","year":"2023","journal-title":"Am J Case Rep"},{"key":"R15-20250922","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bmb\/ldv003","article-title":"Tuberculous meningitis: advances in diagnosis and treatment","volume":"113","author":"Torok","year":"2015","journal-title":"Br Med Bull"},{"key":"R17-20250922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/814943","article-title":"Pathogenesis immunology, and diagnosis of latent mycobacterium tuberculosis infection","volume":"2011","author":"Ahmad","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"R18-20250922","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against mycobacterium tuberculosis in humans","volume":"119","author":"Bruns","year":"2009","journal-title":"J Clin Invest"},{"key":"R19-20250922","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/JS9.0000000000000373","article-title":"The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines","volume":"109","author":"Sohrabi","year":"2023","journal-title":"Int J Surg"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:02:27Z","timestamp":1758524547000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003450","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"2025-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}